Clinical Trial Update: Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating luspatercept in combination with lenalidomide (L2) for lower-risk non-del(5q) myelodysplastic syndromes has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Reblozyl (luspatercept) (luspatercept)
• Revlimid (lenalidomide) (lenalidomide)

Snippet

Sponsor: Mikkael Sekeres, MD | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: SUSPENDED